Reducing residual risk for patients on statin therapy: The potential role of combination therapy

被引：54

作者：

Davidson, MH ^{[1
]}

机构：

[1] Rush Univ, Coll Med, Med Ctr, Chicago, IL 60610 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2005年 / 96卷 / 9A期

关键词：

D O I：

10.1016/j.amjcard.2005.08.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cholesterol-lowering therapy with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, has been established as an effective method of reducing death and myocardial infarction among patients with coronary artery disease (CAD). However, a significant number of patients receiving statin therapy continue to have high residual risk. An important clinical challenge exists in reducing residual CAD risk with optimal therapies without increasing adverse effects. Combination therapy appears most appropriate for patients with a high rate of events of residual risk despite optimal statin therapy. This article discusses the role of combination. therapy in managing CAD and in achieving optional targets in high-risk patient populations. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：3K / 13K

页数：11

共 36 条

[1] Risk of adverse events with fibrates [J].

Alsheikh-Ali, AA ;

Kuvin, JT ;

Karas, RH .

AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (07) :935-+

[2]

ALSHEIKHALI AA, 2004, CIRCULATION S3, V110, P813

[3] Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].

Cannon, CP ;

Braunwald, E ;

McCabe, CH ;

Rader, DJ ;

Rouleau, JL ;

Belder, R ;

Joyal, SV ;

Hill, KA ;

Pfeffer, MA ;

Skene, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504

[4] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[5] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[6]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

[7] Clinical significance of statin pleiotropic effects - Hypotheses versus evidence [J].

Davidson, MH .

CIRCULATION, 2005, 111 (18) :2280-2281

[8] Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations [J].

Davidson, MH ;

Maki, KC ;

Pearson, TA ;

Pasternak, RC ;

Deedwania, PC ;

McKenney, JM ;

Fonarow, GC ;

Maron, DJ ;

Ansell, BJ ;

Clark, LT ;

Ballantyne, CM .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (04) :556-563

[9] Beneficial cardiovascular pleiotropic effects of statins [J].

Davignon, J .

CIRCULATION, 2004, 109 (23) :39-43

[10] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].

Downs, JR ;

Clearfield, M ;

Weis, S ;

Whitney, E ;

Shapiro, DR ;

Beere, PA ;

Langendorfer, A ;

Stein, EA ;

Kruyer, W ;

Gotto, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622

← 1 2 3 4 →